BioCryst Q1 ORLADEYO revenue $68.4M (+38% YoY); net loss narrows to $53.3M

BIOCRYST PHARMACEUTICALS INC

2023-Q1 EPS reported -$0.28 revenue$68,778,000

ORLADEYO net revenue $68.4M in Q1 2023 (+37.6% YoY); 46% more U.S. patients on therapy vs Q1 2022.
Over 1,000 U.S. patients on ORLADEYO; new patient start forms up 20% YoY in Q1.
Full-year 2023 ORLADEYO net revenue guidance set at no less than $320M.
Entered new $450M loan agreement with Pharmakon; $300M drawn to repay Athyrium debt.
R&D expense reduced 26% YoY to $48.4M; SG&A rose 39.6% to $47.9M on commercial investment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOCRYST PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: revenue $68.8 million, net income Net loss of $53.3 million, or $0.28 per share, EPS $0.28 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $68.8 million
Net income: Net loss of $53.3 million, or $0.28 per share
EPS: $0.28 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

For the three months ended March 31, 2023, total revenues were $68.8 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOCRYST PHARMACEUTICALS INC updated its full year 2023 guidance (reaffirmed).

Period: full year 2023
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-002790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.